At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Pitavastatin (NK-104) +1 moredrug
Likely dose
Pitavastatin (NK-104) 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug-Drug Interaction Study to Assess the Effects of Steady-State Lopinavir/Ritonavir on Pitavastatin in Healthy Adult Volunteers
In Brief
A Phase 4 clinical trial evaluating Pitavastatin (NK-104) and Lopinavir/ritonavir for Healthy Volunteers. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This is a Phase 4, single center, open label, fixed-sequence, 2-way drug-drug interaction study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedJan 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedJan 27, 2010
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.4 years ago
Interventions
Pitavastatin (NK-104)drug
pitavastatin (NK-104) 4 mg once daily (QD)
Lopinavir/ritonavirdrug
lopinavir/ritonavir 800 mg/200 mg